Diabetes Drugs Market to Reach US$ 78,261.7 Mn by 2026, Deriving Growth from Increasing Drug Approvals, says Fortune Business Insights

Key companies covered in the Diabetes Drugs Market report include Novo Nordisk A/S, Sanofi, Merck KGaA & Co., Inc., Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Novartis AG, Johnson & Johnson Services, Inc., and Bayer AG.

Pune, June 26, 2019 (GLOBE NEWSWIRE) -- The global Diabetes Drugs Market derives growth from advancements in drug delivery systems. According to a report published by Fortune Business Insights, titled “Diabetes Drugs Market: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 48,753.1 Mn in 2018. Fortune Business Insights has predicted that the market will be valued at US$ 78,261.7 Mn by the end of 2026, thereby exhibiting a CAGR of 6.1%.

Availability of Low-Cost Insulin to Boost the Market

Insulin is one of the most widely used drugs for the treatment of diabetes. The exceptional properties and clinical efficacy of insulin have led to a rising uptake. Despite high efficacy, the cost associated with insulin has been a barrier towards the growth of insulin. Considering this factor, many companies are exploring potential ways to the reduced cost associated with insulin for management of diabetes. In 2019, Eli Lilly and Company, launched a new insulin drug, that was almost half the price of its previous brands. Eli Lilly announced the low-cost insulin ‘Lispro’, a product that was priced significantly less than its previous Humalog injection. Fortune Business Insights’ latest report on the global Diabetes Drugs Market is an encompassment of such product advancements. The report gauges the impact of product innovations, similar to Lispro, on the global market.


Sample PDF https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetes-drugs-market-100570


Encouraged by High Demand, Glenmark Extends Insulin Sales in India

In 2019, Glenmark Pharmaceuticals announced that it plans to bring its Remogliflozin Etabonate to India. The high demand for diabetes drugs in India has influenced Glenmark’s latest move. Additionally, a huge diabetic patient pool has also contributed to the high demand for diabetes drugs in India. Such competitor moves have aided the growth of the global Diabetes Drugs Market. The report includes company activities, similar to the aforementioned case. The report includes detailed analysis of company activities such as takeovers, mergers and acquisitions, agreements, and investment.

Increasing Drug Approvals Have a Positive Impact on Overall Market

The high prevalence of diabetes on a global scale has paved way for several clinical trials. Increasing drug approvals have aided the growth of the global Diabetes Drugs Market. Novo Nordisk’s 2018 launch of Ozempic and Fiasp is a perfect example of the aforementioned case. Additionally, the company received approval from the Food and Drug Administration and this has aided the business expansion of Novo Nordisk. The company’s latest drug approvals will bode well for the global diabetes market and is likely to enable growth of the market in the coming years.

Fortune Business Insights has summarized the impact of several companies on the global Diabetes Drugs Market. Furthermore, Fortune Business Insights has labelled out leading companies that have made significant contributions to the growth of the global Diabetes Drugs Market.



Speak to Analyst: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/diabetes-drugs-market-100570


Key companies covered in the report


Browse Complete Report Details Enabled with Complete Tables and Figures:

https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570


Table of Content:

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities

  • Key Insights
    • Prevalence of Diabetes – For Key Countries, 2018
    • Pipeline Analysis
    • Key Industry Developments –Mergers, Acquisitions and Partnerships
    • Introduction of New Drugs/Approvals (by major players)
    • Overview of Regulatory Scenario of Key Countries/ Regions

  • Global Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary

    • Market Analysis, Insights, and Forecast – By Drug Class
      • Insulin
      • DPP-4Inhibitors
      • GLP-1Receptor Agonists
      • SGLT2 Inhibitors
      • Others

    • Market Analysis, Insights, and Forecast – By Diabetes Type
      • Diabetes1
      • Diabetes2

    • Market Analysis, Insights, and Forecast – By Route of Administration
      • Oral
      • Subcutaneous
      • Intravenous

    • Market Analysis, Insights, and Forecast – By Distribution Channel
      • Online pharmacies
      • Hospital Pharmacies
      • Retail Pharmacies

    • Market Analysis, Insights, and Forecast – By Region
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/diabetes-drugs-market-100570


Browse Related Reports:

  • Multiple Sclerosis Drugs Market Size, Share and Global Trend By Drug Class (Immunomodulatory, Immunosuppressant, Interferons, Others), By Route of Administration (Oral, Injection), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Stores), and Geography Forecast till 2025

  • Orphan Drugs Market Size, Share and Global Trend by Therapy Area (Oncology, Blood, CNS, Endocrine, Cardiovascular, Respiratory, Immunomodulatory), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales) and Geography Forecast till 2025

  • Hemophilia Drugs Market Size, Share and Global Trend by Disease Indication (Hemophilia A, B & C), Therapy Type (Recombinant Therapy, Plasma therapy & Others), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2025

  • Contraceptive Drugs Market Size, Share and Global Trend by Product Type (Oral, Injectable, Patches), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel & NGOs) and Geography Forecast till 2025

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. 

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. 

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.


Contact us:

Fortune Business Insights Pvt. Ltd. 
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
US :+1-424-253-0390
UK :+44-2071-939123
APAC :+91-744-740-1245
Email: sales@fortunebusinessinsights.com 
Website: https://www.fortunebusinessinsights.com

Attachment